New drug aims to stop Post-Surgery breathing danger

NCT ID NCT06137638

Not yet recruiting Prevention Sponsor: Enalare Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether the drug ENA-001 can prevent respiratory depression (dangerously slow or shallow breathing) after major surgery under general anesthesia. About 200 adults having elective surgery will receive either ENA-001 or a placebo as an IV drip. The study is double-blind, meaning neither patients nor doctors know who gets the real drug. The main goal is to see if ENA-001 improves carbon dioxide levels in the blood, a key sign of healthy breathing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ENA-001 (given as an IV infusion)
What this could lead to: If it works, this could lead to a new way to prevent dangerous shallow breathing after major surgery, reducing complications and ICU stays.
What could go wrong: This is an early Phase 2 trial with only 200 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY DEPRESSION

More trials for these conditions

Other studies related to the condition(s) this trial covers.